Form 8-K - Current report:
SEC Accession No. 0001193125-25-156440
Filing Date
2025-07-08
Accepted
2025-07-08 08:19:11
Documents
16
Period of Report
2025-07-08
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d83626d8k.htm   iXBRL 8-K 33281
2 EX-5.1 d83626dex51.htm EX-5.1 9625
3 EX-99.1 d83626dex991.htm EX-99.1 11845
7 GRAPHIC g83626g0707151441952.jpg GRAPHIC 1476
8 GRAPHIC g83626g99t49.jpg GRAPHIC 10502
  Complete submission text file 0001193125-25-156440.txt   189151

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rxrx-20250708.xsd EX-101.SCH 2855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rxrx-20250708_lab.xml EX-101.LAB 17234
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rxrx-20250708_pre.xml EX-101.PRE 10815
18 EXTRACTED XBRL INSTANCE DOCUMENT d83626d8k_htm.xml XML 3535
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

EIN.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40323 | Film No.: 251109568
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)